Member Info for euclid55

China's New Outbreak Shows Signs the Virus Could Be Changing

Chinese doctors are seeing the coronavirus manifest differently among patients in its new cluster of cases in the northeast region compared to the original outbreak in Wuhan, suggesting that the pathogen may be changing in unknown ways and complicating efforts to stamp it out.

https://www.bloomberg.com/news/articles/2020-05-20/china-sees-signs-new-cluster-carries-virus-longer-than-in-wuhan

Part IV -Aptamers in the battle against COVID19
Published on May 19, 2020

Our success continues. Towards the end of last week, I showed that our lab team have successfully isolated a population of aptamers which have preferential binding to the spike protein (S1) from SARS-CoV-2. While the aptamer population did show some interaction with the spike proteins from SARS and MERS; the interaction was significantly stronger with the spike from SARS-CoV-2 which is indicative of a population consisting of individual aptamers which are specific and others which are cross reactive.

Yet again I am incredibly proud of my team for pulling out all the stops and working over the weekend to characterise the monoclonal aptamers. We are pleased to share data to demonstrate examples of both cross reactive and specific aptamers against SARS-CoV-2.

https://www.linkedin.com/pulse/part-iv-aptamers-battle-against-covid19-arron-tolley/?trackingId=Ui7LWY%2B6q4HFo4%2B0laiiEA%3D%3D

JaredMcnulty6

The world's first UV area imaging detector

see pdf document below with further details of their unique imaging detector

http://www.labhoo.com/brochures/b5425_actipix_d100_brochure.pdf

Dr Mebs Surve, Paraytec?s Business Development Manager, said "We were literally speechless when we realised we had won the Pittcon Silver Award. This is global recognition at the highest level, confirming our belief in the importance of the technology. The message is that, of all the new scientific and analytical instruments launched in the last year, the ActiPix is considered to be one of the most significant in contributing technology advances which will impact scientific instruments of the future."

The editors? panel gave the Gold award to $1 Billion American company Waters Corporation, and equal Silver to Paraytec alongside Thermo Fisher Scientific, a global corporation with an annual turnover of $9 Billion. Paraytec?s founder and CSO, Professor David Goodall, commented: ?This award puts our technology up with that of the world?s largest blue chip scientific companies, which is an astounding achievement.

http://www.paraytec.com/news-events/post36/media-release-paraytec-wins-p.html

The ActiPix D100 is currently in early stage sales to end users and development partners in the UK, USA and Europe. The technology is already opening up important new applications and is literally changing the face of UV absorbance detection, one of the most widely used analytical techniques in the world.

Jim Lenke of protein sample preparation instrument company Protea Biosciences in West Virginia has been using the ActiPix for several months and has been "astounded" by its capabilities. Dr Lenke commented "This is a detector with so much potential that it is bound to have an impact on key discoveries for years to come."

http://www.paraytec.com/news-events/post36/media-release-paraytec-wins-p.html

Paraytec wins Pittcon 2007 International Editors? Choice Award against blue-chip competition

UK-based scientific instrument company, Paraytec, has shot to global attention with the announcement that it has won one of the most important international technology awards in its sector. Paraytec?s ActiPix UV detection instrument was awarded the Pittcon 2007 Editors? Choice Silver Award when it was featured as a new product at the world?s largest meeting for laboratory instrumentation and scientific equipment, held last week in Chicago.

The editors? panel gave the Gold award to $1 Billion American company Waters Corporation, and equal Silver to Paraytec alongside Thermo Fisher Scientific, a global corporation with an annual turnover of $9 Billion. Paraytec?s founder and CSO, Professor David Goodall, commented: ?This award puts our technology up with that of the world?s largest blue chip scientific companies, which is an astounding achievement.?

Paraytec?s CEO, Carolyn Parkinson, said ?For a small company from Yorkshire to have its first product voted number two in the world demonstrates the importance of this technology on the global stage.

he technology is already opening up important new applications and is literally changing the face of UV absorbance detection, one of the most widely used analytical techniques in the world. Jim Lenke of protein sample preparation instrument company Protea Biosciences in West Virginia has been using the ActiPix for several months and has been "astounded" by its capabilities. Dr Lenke commented "This is a detector with so much potential that it is bound to have an impact on key discoveries for years to come."

http://www.paraytec.com/news-events/post36/media-release-paraytec-wins-p.html

Professor David Goodall

As an Emeritus Professor, my current activities in the Department are principally via our spin-off company Paraytec Limited. Our most recent research in analytical science, carried out in partnership with Experimental Officer Dr Ed Bergström, has been focused on development and applications of novel miniature UV area imaging detectors based on active pixel sensor (APS) technology.

Much of our work has exploited synergy with electronics engineers, biologists and major pharmaceutical and biopharmaceutical companies. APS devices are effectively cameras on chips, and our innovations allow them to be used in applications including

eal time visualisation of separations and reactions
Lab-on-capillary, visualising species before and after reaction and separation stages in capillary flow lines
Lab-on-a-chip, with UV imaging of processes in flow channels
Imaging dissolution of pharmaceutical dosage forms
Enzyme assays and biocatalysis
High precision ion analysis in pharmaceuticals and foods
Simultaneous quantification and sizing of proteins and biopharmaceuticals
Multiplexed detection in capillary electrophoresis (CE) and capillary liquid chromatography (LC)
High sensitivity parallel detection of protein digest

https://www.york.ac.uk/chemistry/staff/academic/emeritus/professordavidgoodall/

Paraytec’s multi-award winning product, the ActiPix D100, is the world’s first quantitative UV area imaging system. As well as providing superior performance over existing micro and nano flow detectors the patented.

Applications for the company’s patented ActiPix technology can be broadly classified into two types, area imaging or capillary based.

Capillary based applications include use of the ActiPix D100 as a sensitive and selective detector for multiplexed capillary electrophoresis

https://www.labmate-online.com/news/microscopy-and-microtechniques/4/paraytec-ltd/bibliography-demonstrates-applications-of-uv-area-imaging/7152
_ _ ___________________________________________________________________________________

Rapid Aptamer Selection Using Capillary Electrophoresis.

Recently, the high resolving power of capillary electrophoresis
(CE) has been used to select high-affinity aptamers, reducing the
process from weeks to only a few days, using a process known
as CE-SELEX. In CE selections, nucleic acid sequences that
bind the target undergo a mobility shift, migrating at a different
rate allowing separation and collection of high-affinity aptamers
from the non-binding sequences.

Isolating aptamers using capillary
electrophoresis (CE) combines extreme resolving power and highly stringent yet flexible selection conditions allowing highaffinity aptamers to be obtained in only 2-4 rounds of selection.4,5
Compared to conventional methods, which require 8-15 rounds
and tedious negative selection, CE is a simple and efficient
technique that dramatically decreases the time and resources
required for isolation of new aptamer sequences.

https://sciex.com/Documents/tech%20notes/ce-selex-rapid-aptamer-selection.pdf

Linkedin Feedback:

See profile for Arron Tolley
Arron Tolley Author
CEO at Aptamer Group
1w
I’d like to that my protein team for this as they have worked incredibly hard this last week to get the work done. Banushan Balansethupathy Harriet ***** Joseph Reed Phoebe O'Hara Laura Milburn

Like Arron Tolley’s comment
1 Like 1 Like on Arron Tolley’s comment

2 Replies 2 Replies on Arron Tolley’s comment
Load previous replies Load previous replies on Arron Tolley’s comment
See profile for Arron Tolley
Arron Tolley Author
CEO at Aptamer Group
2d
The aptamers we are developing are platform agnostic. We are working with multiple end users for access to the technology we are developing.

Like Arron Tolley’s comment
1 Like 1 Like on Arron Tolley’s comment

See profile for Sasha Thomas
Sasha Thomas out of network 3rd+
Neuroscience and Biochemistry
13h
Tom Speedy we can make aptamers?

Like Sasha Thomas’ comment

See profile for Sammie Parvez
Sammie Parvez out of network 3rd+
Business Analyst at Barclays
1w
(edited)
This sounds promising.. what are the next steps you have to do in order to determine that this is a viable testing tool for CV19?

Like Sammie Parvez’s comment

See profile for Henrik Luessen
Henrik Luessen out of network 3rd+
Managing Director Tytonis BV
1w
Wow, impressive to see the power of your aptamer technology. No antibody could achieve that !

Like Henrik Luessen’s comment

See profile for Elena Pérez Ruiz
Elena Pérez Ruiz out of network 3rd+
R&D and Innovation consultancy | PhD | Analytical chemist, expert in bio(nano)technology
3d
Impressive dissociation curves!

Like Elena Pérez Ruiz’s comment

See profile for Peter Cousins
Peter Cousins • Following
Technical Director at Aptamer Diagnostics Ltd
1w
That’s fantastic news. Well done guys!

Like Peter Cousins’ comment

See profile for Steve Hull
Steve Hull out of network 3rd+
--
1w
Onwards and upwards with quality testing tools

This project brings together the innovative detection technology of Paraytec Ltd with the target recognition technology provided by Aptamer Diagnostic Ltd to create the next generation of detection instruments. These novel platforms will allow rapid field and point-of-care based diagnosis based on multiple markers of disease or contamination.

Simultaneous detection of multiple markers will reduce the ambiguity associated with diagnostic systems which look for single markers. It will also save both time and expense associated with routine laboratory based sample screening, allowing them to focus on samples where more detailed analysis is required.

https://gtr.ukri.org/projects?ref=131249

Easy to sell 50,000 now - seems they want stock

Recently GSK invested $250 million in Vir Biotechnology Inc3 to develop potential antibody treatments for COVID-19 by selecting antibodies from recovered patients, and AstraZeneca also recently announced that it would start a programme to find new monoclonal antibodies that block the spike/ACE2 interaction4.

There is significant potential for a therapy that could help prevent infection and limit the progression of the disease, providing immediate benefit to patients. With a large and well-resourced partner, a neutralising Affimer therapy could potentially be developed more quickly than a vaccine and we believe that the likelihood of success would be high.

https://www.investegate.co.uk/avacta-group-plc--avct-/rns/sars-cov-2-neutralising-affimers/202005150700059841M/

also another thumbs up from below:

Claire Shepherd
Claire has a account
Biacore Application Specialist at Cytiva (formerly GE Life Sciences)

https://www.linkedin.com/pulse/rapid-aptamer-discovery-track-resolve-covid-19-reagents-arron-tolley/

Amrit Nahal - Equity sales at Allenby Capital gave positive feedback to Aptamer's report 13/05/2020

https://www.linkedin.com/pulse/rapid-aptamer-discovery-track-resolve-covid-19-reagents-arron-tolley/

Good idea to follow the contacts / Bod's at these affiliated co's of BRH - ro see what they are saying & reporting re Covid 19

Pyreos supplied its dual channel analogue infrared detectors for capnography to leading European and Asian medical equipment manufacturers for several years and is in development with a major global customer. The company is also working with other established capnography manufacturers to support accelerated development programmes launched during the pandemic.

As a result of the pandemic, it has ramped the production of its ezPyro, anaesthesia and CO2 detection products to support OEMs manufacturing of these vital systems worldwide.

The company is also supporting research and development projects in two universities on ventilation and breath measurement by offering advice, reference designs and design help. This support includes open-sourcing of relevant reference designs.

https://pyreos.com/press-releases/pyreos-gives-priority-to-shipping-pyroelectric-detectors-for-medical-breath-monitoring-systems-used-with-ventilators

Siemens contributed seed technology in the form of proprietary developments and a patent portfolio for ceramic thin film MEMS IR sensor technology. Siemens had already invested over 75 man years (around €10m) in this technology and spun it out into Pyreos to ensure broader market-based growth.

Since then, Pyreos has optimised the sensor technology and combined it with additional semiconductor process developments and packaging techniques to create a new range of infrared sensor products. Pyreos has also continued to develop the patent portfolio and now has 27 patent families.

In addition, Pyreos benefits from an ongoing relationship and support from Siemens and Bosch with whom we have technical cooperation.

https://pyreos.com/the-team/about-us

a good read below from another co that BRH has a stake in

Pyreos CEO Andrew Wallace explained, “Demand for medical products has increased several times over in just a few weeks. Orders for our medical and related products have already locked in 50% annual growth at Pyreos in just the first few months of the year.

We value the SMC’s openness to quickly agreeing safe working practices and providing a way to accelerate production.”

https://pyreos.com/press-releases/pyreos-raises-output-at-scotlands-smc-for-rising-covid-19-healthcare-demand

If you held these in early / late march at a low of 7p - you could of sold out at 49p 0r 700% - wonder if Dave4545 on ADVFN is still in or sold out after a suttle ramp from him - haven't seen any more posts from him lately